valbenazine

inhibits vesicular monoamine transporter 2 (VMAT2); used to treat tardive dyskinesia; structure in first source

Also Known As:

(2R,3R,11BR)-9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2H- benzo(a)quinolizin-2-yl l-valinate; Ingrezza; NBI-98854; valine 1,3,4,6,7,11b-hexahydro-9,10-dimethoxy-3-(2-methylpropyl)-2H-benzo(a)quinolizin-2-yl ester

Networked: 85 relevant articles (15 outcomes, 18 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	O'Brien, Christopher F: 12 articles (01/2021 - 10/2015)
2.	Burke, Joshua: 11 articles (01/2021 - 10/2015)
3.	Liang, Grace S: 10 articles (01/2021 - 01/2017)
4.	Jimenez, Roland: 7 articles (01/2021 - 10/2015)
5.	Correll, Christoph U: 7 articles (01/2019 - 01/2016)
6.	Kane, John M: 5 articles (01/2019 - 01/2017)
7.	Grigoriadis, Dimitri E: 4 articles (01/2020 - 01/2017)
8.	Factor, Stewart A: 4 articles (01/2019 - 10/2015)
9.	Hauser, Robert A: 4 articles (01/2018 - 10/2015)
10.	Lindenmayer, Jean-Pierre: 3 articles (01/2022 - 11/2019)

Related Diseases

1.	Tardive Dyskinesia 06/01/2015 - "The FDA lowered approval hurdles for valbenazine due to a successful Phase II trial, which showed a distinctive improvement in tardive dyskinesia symptoms during valbenazine administration. " 10/01/2015 - "NBI-98854 significantly improved tardive dyskinesia and was well tolerated in patients. " 11/01/2017 - "AIMS and CGI-TD measures indicated sustained tardive dyskinesia improvement, with scores returning toward baseline after 4 weeks of valbenazine washout. " 01/01/2018 - "This review has found that the use of valbenazine or extract of Ginkgo biloba may be effective in relieving the symptoms of tardive dyskinesia. " 07/01/2017 - "Valbenazine for tardive dyskinesia: A systematic review of the efficacy and safety profile for this newly approved novel medication-What is the number needed to treat, number needed to harm and likelihood to be helped or harmed?"
2.	Dyskinesias (Dyskinesia) 01/01/2019 - "The least squares mean improvement from baseline to week 6 in Abnormal Involuntary Movement Scale total score was significantly greater with valbenazine (low dose: -2.4; high dose: -3.2; both, P < 0.001) versus placebo (-0.7). " 01/01/2019 - "To estimate an minimal clinically important difference for the Abnormal Involuntary Movement Scale using valbenazine trial data and an anchor-based method. " 07/01/2017 - "The percentage of responders in the Phase III acute study, as defined by ≥50% reduction from baseline in the Abnormal Involuntary Movement Scale dyskinesia score was 40.0% for valbenazine 80 mg/d vs 8.7% for placebo, yielding a NNT of 4 (95% CI 3-6). " 11/01/2019 - "Valbenazine effects on TD were assessed using the Abnormal Involuntary Movement Scale (AIMS), Clinical Global Impression of Change-TD, and Patient Global Impression of Change. " 10/01/2015 - "Abnormal Involuntary Movement Scale scores for NBI-98854 compared with placebo were significantly reduced (p = 0.0005). "
3.	Mood Disorders (Mood Disorder) 01/01/2019 - "In participants with primary mood disorders, once-daily treatment with valbenazine was generally well tolerated and resulted in 6-week and sustained TD improvements." 01/01/2017 - "Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder." 01/01/2019 - "The effects of valbenazine on tardive dyskinesia in patients with a primary mood disorder." 01/01/2017 - "In addition to long-term efficacy results (presented separately), these results suggest that valbenazine may be appropriate for the long-term management of TD regardless of underlying psychiatric diagnosis (SCHZ disorder or mood disorder)." 01/01/2017 - "The short-term safety profile of once-daily valbenazine (NBI-98854) has been evaluated in several double-blind, placebo-controlled (DBPC) trials in adults with tardive dyskinesia (TD) who had a diagnosis of schizophrenia/schizoaffective (SCHZ) disorder or mood disorder. "
4.	Schizophrenia (Dementia Praecox) 01/01/2017 - "Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder." 01/01/2017 - "The short-term safety profile of once-daily valbenazine (NBI-98854) has been evaluated in several double-blind, placebo-controlled (DBPC) trials in adults with tardive dyskinesia (TD) who had a diagnosis of schizophrenia/schizoaffective (SCHZ) disorder or mood disorder. " 11/01/2017 - "Participants with a DSM-IV diagnosis of schizophrenia, schizoaffective disorder, or a mood disorder who completed the 6-week, double-blind, placebo-controlled period of KINECT 3 were eligible to enter the 42-week valbenazine extension (VE) period and subsequent 4-week washout period. " 01/01/2017 - "Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder." 01/01/2017 - "Once-daily valbenazine significantly improved tardive dyskinesia in participants with underlying schizophrenia, schizoaffective disorder, or mood disorder. "
5.	Psychotic Disorders (Schizoaffective Disorder) 01/01/2017 - "Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder." 11/01/2017 - "Participants with a DSM-IV diagnosis of schizophrenia, schizoaffective disorder, or a mood disorder who completed the 6-week, double-blind, placebo-controlled period of KINECT 3 were eligible to enter the 42-week valbenazine extension (VE) period and subsequent 4-week washout period. " 01/01/2017 - "Once-daily valbenazine significantly improved tardive dyskinesia in participants with underlying schizophrenia, schizoaffective disorder, or mood disorder. " 01/01/2023 - "Serious treatment-emergent adverse events were reported in two participants in the placebo group (colon cancer and psychosis) and one participant in the valbenazine group (angioedema because of allergic reaction to shellfish). " 01/01/2019 - "Valbenazine and Deutetrabenazine as possible treatments for neuroleptic-induced supersensitivity psychosis and antipsychotic dependence."

Related Drugs and Biologics

1.	deutetrabenazine
2.	Vesicular Monoamine Transport Proteins (Vesicular Monoamine Transporter)
3.	Antipsychotic Agents (Antipsychotics)
4.	Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)
5.	Tetrabenazine (Nitoman)
6.	Dopamine (Intropin)
7.	valbenazine
8.	Salts
9.	Reserpine (Serpasil)
10.	Dopamine Receptors (Dopamine Receptor)

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Off-Label Use
3.	Therapeutics